Akademik Veri Yönetim Sistemi
Istanbul Tip Fakultesi Mecmuasi, cilt.58, sa.1, ss.9-14, 1995 (Scopus)
The aim of this study was to evaluate the antihypertensive effects and tolerability of slow release verapamil in patients with mild to moderate essential hypertension. The study material was consisted of 411 (180 males and 231 females; the mean age was 54 ± 9, years; ranged 22-73 years) patients. Slow release verapamil 240 mg once a daily was given to the patients for 4 weeks. The mean value of blood pressure was significantly reduced from 184 ± 14/106 ± 7 mm Hg to 146 ± 18/87 ± 8 mm Hg at the end of the trial (p<0.001 and p<0.001). Heart rate was not significantly changed. Diastolic blood pressure was reduced to 90 mm Hg or below in the 87 % of patients after 4 weeks of treatment. The tolerability of drug was very good in the 58 % of patients, good in 29 %, satisfactory in 10 % and bad in 2 % of patients. The duality of life questionnaires was also done in all patients. The patient response was good in the 33 % of patients, satisfactory in 55 %, average in 11 % and bad in 0.2 %. We conclude that slow release verapamil 240 mg once a daily is an effective and reliable first-step antihypertensive drug, and its effects of quality of life is favorable in patients with mild to moderate essential hypertension.